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Abstract  28 
Objectives: Elevated concentrations of polyamines have been found in urine of patients with malignant tumors, 29 
including ovarian cancer. Previous research has suffered from poorly standardized detection methods. Our liquid 30 
chromatography tandem mass spectrometry (LC-MS/MS) -method is capable of simultaneous standardized 31 
analysis of the majority of known polyamines. LC-MS/MS has not previously been used in the differential 32 
diagnostics of ovarian tumors in postmenopausal women.   33 
Materials and Methods: In this prospective study, postmenopausal women (N = 71) presenting with an adnexal 34 
mass, and as controls, women with genital prolapse or urinary incontinence scheduled for surgery (N = 22), 35 
were recruited to the study. For analysis of the polyamines, a morning urine sample was obtained before 36 
surgery. Preoperative serum CA125 concentrations were determined in the study group.  37 
Results: Twenty-three women with benign and 37 with malignant ovarian tumors were eligible. Of all analyzed 38 
polyamines, only urinary N
1
,N
12
-diacetylspermine (DiAcSpm) showed statistically significant differences 39 
between all groups except controls vs. benign tumors. DiAcSpm was elevated in malignant vs. benign tumors (p 40 
< 0.001), in high grade vs. low malignant potential tumors (p < 0.001), in stage III-IV vs. stage I-II cancers (p < 41 
0.001), and even in early-stage cancer (stage I-II) vs. benign tumors (p = 0.017). DiAcSpm had better sensitivity 42 
(86.5 %) but lower specificity (65.2 %) for distinguishing benign and malignant ovarian tumors than CA125 43 
with cut-off value of 35 kU/L (sensitivity 75.7 % / specificity 69.6 %).  44 
Conclusions: Urinary DiAcSpm seems to be able to distinguish benign and malignant ovarian tumors as well as 45 
early and advanced stage, and low malignant potential and high grade ovarian cancers from each other, 46 
respectively.   47 
Keywords: LC-MS/MS, ovarian tumor, ovarian cancer, DiAcSpm, polyamine 48 
49 
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Introduction 50 
Ovarian cancer is the leading cause of deaths due to gynecological cancer in the U.S. and Europe. The lack of 51 
specific symptoms makes the diagnosis of ovarian cancer difficult, with ultrasound being typically the first 52 
imaging test used to distinguish benign and malignant tumors from each other. Ultrasound features combined 53 
with CA125 and menopausal status have been used to calculate the Risk of Malignancy Index (RMI).
1  
A major 54 
problem in ultrasound imaging is the relatively large number of false positive results. Unfortunately, CA125 55 
antigen lacks sensitivity even in the postmenopausal setting, as it is not expressed by approximately 20 % of 56 
early stage ovarian cancers.
2 
  57 
Polyamines are molecules essential for nearly all living organisms with critical roles in cell signaling and 58 
growth in vertebrates. Putrescine, spermidine and spermine are the most common polyamines detected in 59 
mammals. Polyamines exist in urine mainly in acetylated forms.
3 
 Increased polyamine concentrations are found 60 
during active cellular proliferation, like in patients with cancer.
4 
 In fact, ovarian cancer was one of the first 61 
cancers linked to polyamines.
5 
 These early studies were hampered by methodological problems, but 62 
subsequently, the development of gas chromatography-mass spectrometry enabled quantitation of both free and 63 
acetylated polyamines in human urine without hydrolysis of polyamines.
6 
 Recently, an optimized liquid 64 
chromatography tandem mass spectrometry (LC-MS/MS) -method has been developed, which allows for a 65 
simultaneous analysis of up to 14 polyamines in different forms in urine.
7 
  66 
The present study was undertaken as a proof of concept study to explore the usefulness of LC-MS/MS in 67 
differential diagnostics of ovarian tumors. 68 
 69 
Materials and Methods 70 
Patients 71 
From May 2013 through March 2016, 71 patients presenting with an abnormal adnexal mass and scheduled for 72 
surgery at the Department of Obstetrics and Gynecology of Tampere University Hospital, were prospectively 73 
recruited to the study. They had to be at least 50 years old, and the only exclusion criterion was an ongoing 74 
treatment for cancer. Besides pelvic examination, a vaginal ultrasound scan was performed, and a serum sample 75 
for CA125 was obtained from each patient. The final sample size was 60 patients, after exclusion of ineligible 76 
patients (Fig. 1).   77 
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Twenty-two postmenopausal women scheduled for surgery because of genital prolapse or urinary incontinence 78 
from May 2013 through April 2014, were recruited as controls. One patient of the control group had to be 79 
excluded because of an incidental endometrial adenocarcinoma. All subjects provided a morning urine sample at 80 
the day of operation. The samples were stored at -70° C until analysis for polyamines.  81 
All participants gave their informed consent to the study, which was approved by the Ethics Committee of 82 
Tampere University Hospital (ETL R10066).  83 
LC-MS/MS-analysis 84 
The LC-MS/MS-analysis was conducted at the University of Eastern Finland (Kuopio, Finland) and was 85 
performed using the previously described method.
7 
 In short, the chromatographic separations were carried out 86 
using a reversed phase column (Phenomenex Kinetex C18 150 mm × 2.1 mm, 2.6 µm) and 0.1% 87 
heptafluorobutyric acid as the evaporative ion-pairing reagent. Detection was performed with Agilent 6410 88 
triple quadrupole mass spectrometry equipped with an electrospray ionization source, and using selected 89 
reaction monitoring method. Deuterated polyamines were used as stable internal standards in quantification. 90 
Polyamine concentrations were normalized using creatinine concentration. The concentrations are expressed as 91 
µmol of polyamine per gram of creatinine. 92 
The creatinine concentrations of the urine samples were determined enzymatically using Cobas 6000, C 501-93 
module (Roche diagnostics GmbH, Mannheim, Germany) at Fimlab Laboratories. 94 
Statistical analysis 95 
No formal sample size calculations were made due to the preliminary nature, of the study. The statistical 96 
analysis was performed by using MATLAB version R2016b. The normality of the distributions of continuous 97 
variables was evaluated by Kolmogorov-Smirnov tests. Due to the skewness of the distributions, the differences 98 
in polyamine concentrations between the distinct groups were analyzed by Wilcoxon rank sum test. The 99 
differences in the concentrations of polyamines are visualized by box plots. A probability value of < 0.05 was 100 
considered as statistically significant. All tests were two-sided. To compare the predictive performance of 101 
DiAcSpm and CA125, a receiver operating characteristics (ROC) analysis was accomplished.  102 
 103 
 104 
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Results  105 
Patients and tumors  106 
All 81 women in the final study population were over 50 years old and postmenopausal. The median age (75 107 
years; range 55-83) in the control group was significantly higher than in the groups with benign (65 years; range 108 
51-73) and malignant tumors (64 years; range 51-86), respectively (p = 0.02). Three of the controls and four of 109 
the cases had used systemic hormonal therapy before surgery. Five patients (one in the control group, one with a 110 
benign and three with a malignant ovarian tumor) had previously been treated for breast cancer and one patient 111 
(with a malignant ovarian tumor) for thyroid cancer, but all of them were disease-free at the time of sampling.   112 
Of the ovarian tumors, 23 were benign and 37 were malignant (Fig. 1). The benign group consisted of 11 serous 113 
and two mucinous cystadenomas, two fibromas, five simple and two endometriotic cysts, and one necrotized 114 
cyst. Eighteen of the malignant tumors were of low malignant potential (four serous and five mucinous 115 
borderline tumors, three mucinous adenocarcinomas, four granulosa cell tumors, one Sertoli-Leydig cell tumor, 116 
and one endometrioid adenocarcinoma). Eighteen of the high grade tumors were serous carcinomas (HGSC) and 117 
one was a carcinosarcoma. One of the patients with HGSC had two primary tumors, or the stage IIIC ovarian 118 
cancer and an invasive ductal grade 3 breast cancer, which were operated on at the same session.  119 
The median serum concentrations of CA125 were 18.0 kU/L (range, 5-1,984), 53.5 kU/L (range, 7-841), and 120 
546.0 kU/L (range, 22-8,152) in the patients with benign tumors, with low malignant potential tumors, and with 121 
high grade tumors, respectively. The difference of the tumor marker concentration between the groups was 122 
statistically significant (p < 0.001). 123 
Urinary polyamines and their metabolites  124 
The polyamines and their metabolites detected by the LC-MS/MS are given in Table 1. Six polyamines, or, 125 
acetylated putrescine (AcPut), acetylated cadaverine (AcCad), N
1
-acetylated spermidine (N
1
AcSpd), N
8
-126 
acetylated spermidine (N
8
AcSpd), DiAcSpd, and DiAcSpm were constantly found in all urine samples, but only 127 
DiAcSpm showed statistically significant differences between all groups except between controls and benign 128 
ovarian tumors (Fig. 2, Fig. 3). The polyamine concentrations were independent of body mass index (BMI; data 129 
not shown).  130 
A detailed description of the urinary concentrations of DiAcSpm in different settings is given in Table 2. There 131 
were no differences between the women with genital prolapse or urinary incontinence and the women with 132 
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benign tumors. Of the women with malignant tumors, the ones with high grade and advanced stage tumors had 133 
the highest urinary concentrations of DiAcSpm. However, the concentrations were significantly higher also in 134 
women with low malignant potential and early stage tumors than in the controls.  135 
Besides DiAcSpm, there was also a significant difference in concentrations of DiAcSpd, N
1
AcSpd and 136 
N
8
AcSpd between low malignant potential and high grade malignant ovarian tumors (p values 0.02, 0.004 and 137 
0.013, respectively), and between benign and malignant ovarian tumors in concentrations of DiAcSpd and 138 
N
8
AcSpd (p values 0.015 and 0.042). 139 
Performance of CA125 and urinary DiAcSpm  140 
In distinguishing benign tumors from the malignant ones, the specificity and sensitivity of CA125 (using the 141 
standard used cut-off value 35 kU/L) were 69.6 % and 75.7 %. Correspondingly, the specificity of DiAcSpm 142 
(cut-off value 0.097 μmol/g creatinine) was 65.2 % and sensitivity 86.5 % (Fig. 4). 143 
 144 
Discussion  145 
The main finding of this preliminary study was that urinary concentrations of DiAcSpm are elevated among 146 
postmenopausal women with malignant ovarian tumors as compared to women with benign ovarian tumors or 147 
genital prolapse. Although DiAcSpm concentrations were higher in the case of high grade and advanced stage 148 
cancers than among low malignant potential and early-stage cancers, respectively, there was still a statistically 149 
significant difference in DiAcSpm levels between early-stage (and low malignant potential) and benign tumors.  150 
Previous studies utilized methodology with limited polyamine array and were unable to measure all polyamines 151 
in a single run, which deteriorated repeatability and increased variability of different studies. Another limitation 152 
was that acetylated polyamines, which are highly specific for malignant disease, could not be measured. 153 
Consequently, the earlier research focused on less specific unacetylated polyamines.
8 
 Many methods rely on 154 
derivatization techniques where polyamines are conjugated with other molecules to allow extraction and 155 
analysis.
9 
 This technique is not suitable for the analysis of diacetylated polyamines due to acetylation of active 156 
amino-groups. Our LC-MS/MS method optimized for noninvasive and standardized single-run analysis of urine 157 
can be utilized for simultaneous analysis of up to 14 polyamines in free, mono- and diacetylated forms in human 158 
urine, without any derivatization.
7 
 In the present study, however, 1,3-diaminopropane and putrescine were not 159 
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detectable. Additionally, results concerning diacetylated cadaverine and diacetylated putrescine should be 160 
interpreted with caution, since their analysis is only semiquantitative.
7 
 161 
While we are not aware of any subsequent studies since the report by Suh et al.
10 
, on the urinary polyamine 162 
profile in ovarian cancer, our results are in accordance to previous experience with other tumors. Patients with 163 
non-Hodgkin’s lymphoma, or urogenital cancer (testicular, prostatic, renal and bladder carcinoma) have been 164 
found to have elevated urinary concentrations of DiAcSpm, and those with urogenital cancer also of DiAcSpd.
6, 
165 
11-13 
 In breast cancer, even early stage disease seems to be associated with elevated levels of DiAcSpm in the 166 
urine.
13 
 In colon cancer, urinary DiAcSpm may be a better tumor marker than carcinoembryonic antigen (CEA) 167 
or cancer antigen 19-9 (CA 19-9).
13, 14 
 Besides being predictive markers, there is a possibility that DiAcSpm 168 
and DiAcSpd could be used also as prognostic markers, at least in testicular or prostatic cancer.
11 
 Urinary 169 
DiAcSpm has been shown to be both diagnostic and prognostic marker also for non-small-cell lung cancer.
15, 16 
  170 
In the present study, the performance of CA125 used in the preoperative diagnostic work-up of pelvic tumors, 171 
was poorer than in published large screening studies.
1, 17-20 
 The reason may be by chance only, due to the rather 172 
limited sample size, but the fact that a large portion of the malignant tumors were of low malignant potential or 173 
borderline epithelial, granulosa and Sertoli-Leydig cell tumors, may have contributed to the less than optimal 174 
performance. In any case, urinary DiAcSpm was a more sensitive marker of malignant ovarian tumors than 175 
CA125 with a cut-off value 35 kU/L, while being less specific.  176 
Although the mechanism underlying elevated concentrations of DiAcSpm in the urine of cancer patients is not 177 
completely understood, an increased synthesis of polyamines in proliferating cells, including malignant cells is 178 
well documented. It has been suggested that the increased secretion of DiAcSpm may reflect a defense 179 
mechanism by the organism to lower intracellular polyamine concentrations by acetylating and excreting 180 
polyamines and hence, decreasing the growth rate of the tumor.
8, 13, 21 
 It has also been purported that the 181 
production of DiAcSpm in tumorigenesis may be a result of host macrophage activation.
22 
 182 
The results of the present study are to be considered as preliminary, to be confirmed in larger patient cohorts. 183 
Chronic inflammatory diseases may influence DiAcSpm concentrations. However, in the study of pancreatico-184 
biliary diseases the levels of DiAcSpm in urine were lower in benign inflammatory conditions than in cancers.
23 
 185 
Presence of urinary tract infection may also have a confounding influence on urinary polyamines, increasing 186 
especially the level of putrescine.
24 
 The impact of infection cannot totally be ruled out in the present study, 187 
because a routine urine sample for diagnosing urinary infection was taken only from the patients of the control 188 
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group. Moreover, cadaverine in human urine is suggested to be derived from the gut microbial flora.
24 
 A 189 
limitation of the study is that there were no patients with a benign teratoma, because among benign tumors, 190 
teratomas have been associated with elevated levels of urinary polyamines.
5 
 On the other hand, teratomas are 191 
typically tumors of adolescents and young adults and not of postmenopausal women, the risk population for 192 
ovarian cancer. 193 
Ornithine decarboxylase is one of the key enzymes in polyamine synthesis and is stimulated by estrogens in 194 
estrogen-responsive tissues.
25 
 A previous study found that urinary DiAcSpm values are higher in women than in 195 
men, while postmenopausal women had lower concentrations than premenopausal ones.
26 
 Accordingly, Buyn et 196 
al. showed that premenopausal breast cancer patients had higher (free and monoacetylated) polyamine levels in 197 
serum than postmenopausal ones, whose polyamine levels were similar to healthy controls.
27 
 In our study all 198 
women were postmenopausal, but seven of them used hormone replacement therapy, creating a potential bias. 199 
However, excluding these patients did not alter the results. The control women were older than the ones with 200 
tumors, which may have had impact on the results. However, there was no significant difference between 201 
DiAcSpm levels of control group and women with benign ovarian tumors. One patient in the malignant tumor 202 
group had been treated for breast cancer over five years ago, but she had no signs of recurrence. Another patient 203 
had a grade 3 breast cancer concurrently with the stage IIIC HGSC, which may have affected her DiAcSpm 204 
level. However, her urinary level of DiAcSpm was of similar magnitude as in the patients with advanced high 205 
grade tumors in general.  206 
We used a morning urine sample in our study, which however may not have been necessary. According to a 207 
study on healthy people, a spot urine sample at any time of the day represents the true excretion rate of 208 
DiAcSpm after creatinine normalization.
26 
 Although the LC-MS/MS method is very accurate, it is as such not 209 
suitable for routine clinical use, at least not for time being.
7 
 However, if only one (DiAcSpm) or a few 210 
polyamines need to be analyzed, the analysis could probably be made faster and less expensive to perform. 211 
Alternative methods to measure only urinary DiAcSpm in routine clinical practice include an enzyme-linked 212 
immunosorbent assay (ELISA)
13, 28 
 or a colloidal gold aggregation procedure.
29 
   213 
In conclusion, urinary levels of DiAcSpm were elevated in patients with malignant ovarian tumors, even in 214 
patients with tumors of low malignant potential and early-stage tumors. These preliminary findings suggest that 215 
urinary DiAcSpm may in the future become a useful diagnostic marker for malignant ovarian tumors in the 216 
postmenopausal setting. 217 
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Table 1. The polyamines studied and their urinary concentrations (μmol/g creatinine) in patients with ovarian 287 
tumors and in controls  288 
 289 
  290 
Polyamine 
 
Controls  
(N = 21) 
 
Benign ovarian tumors  
(N = 23) 
Low grade malignant tumors  
(N = 18) 
High grade malignant 
ovarian tumors (N = 19) 
Range 
μmol/g 
creatinine 
 
Detection 
rate 
 
Range 
μmol/g 
creatinine 
 
Detection 
rate 
 
Range 
μmol/g 
creatinine 
 
Detection 
rate 
 
Range 
μmol/g 
creatinine 
 
Detection 
rate 
 
Cad 
 
NA-2.65 13/21 
 
NA-3.94 
 
19/23 
 
NA-20.19 
 
15/18 
 
NA-48.7 
 
9/19 
 
AcCad 
 
0.04-5.64 
 
21/21 
 
0.08-14.26 
 
23/23 
 
0.11-13.08 
 
18/18 
 
0.17-5.57 
 
19/19 
 
DiAcCad 
 
NA-0.48 
 
13/21 
 
NA-0.28 
 
18/23 
 
NA-1.79 
 
12/18 
 
NA-0.63 
 
8/19 
 
AcPut 
 
6.57-19.28 
 
21/21 
 
5.60-28.1 
 
23/23 
 
9.15-41.45 
 
18/18 
 
8.54-50.16 
 
19/19 
 
DiAcPut 
 
NA-0.24 
 
17/21 
 
NA-0.62 
 
18/23 
 
NA-0.75 
 
16/18 
 
NA-0.25 
 
17/19 
 
Spd 
 
NA-0.30 
 
20/21 
 
0.08-0.27 
 
23/23 
 
0.10-0.28 
 
18/18 
 
0.09-0.56 
 
19/19 
 
N1AcSpd 
 
1.78-8.92 
 
21/21 
 
1.04-8.17 
 
23/23 
 
1.39-6.50 
 
18/18 
 
2.52-18.50 
 
19/19 
 
N8AcSpd 
 
1.84-4.75 
 
21/21 
 
1.15-4.69 
 
23/23 
 
1.65-5.03 
 
18/18 
 
2.18-5.99 
 
19/19 
 
DiAcSpd  
 
0.18-0.65 
 
21/21 
 
0.14-1.32 
 
23/23 
 
0.16-1.34 
 
18/18 
 
0.23-1.20 
 
19/19 
 
Spm 
 
NA-0.55 
 
8/21 
 
NA-0.45 
 
12/23 
 
NA-0.25 
 
12/18 
 
NA-0.32 
 
14/19 
 
AcSpm 
 
NA-0.01 
 
3/21 
 
NA-0.01 
 
4/23 
 
NA-0.004 
 
1/18 
 
NA-0.04 
 
7/19 
 
DiAcSpm 
 
0.06-0.20 
 
21/21 
 
0.04-1.02 
 
23/23 
 
0.06-0.37 
 
18/18 
 
0.14-2.37 
 
19/19 
 
NA; analyzed concentration was below the lowest calibration point 
Cad, cadaverine; AcCad, acetylated cadaverine; DiAcCad, diacetylated cadaverine; AcPut, acetylated putrescine; DiAcPut, diacetylated 
putrescine; Spd, spermidine; N1AcSpd, N1-acetylated spermidine; N8AcSpd, N8-acetylated spermidine; DiAcSpd, N1,N8-diacetylspermidine; 
Spm, spermine; AcSpm, acetylated spermine; DiAcSpm, N1,N12-diacetylspermine  
13 
 
 
Table 2. The urinary concentrations of N
1
,N
12
-diacetylspermine (DiAcSpm) (μmol/g creatinine) in patients with 291 
ovarian tumors and in controls and comparisons between the groups  292 
                                N
1
,N
12
-diacetylspermine (DiAcSpm) (μmol/g creatinine)  
 Mean SD Median Min. Max. Comparison p 
value 
Controls 0.10 0.04 0.09 0.06 0.20 vs. benign 
tumors 
NS 
 
Benign tumors 
 
0.15 
 
0.21 
 
0.08 
 
0.04 
 
1.02 
  
 
All malignant 
tumors 
 
0.54 
 
0.62 
 
0.26 
 
0.06 
 
2.37 
 
vs. benign 
tumors 
 
< 
0.001 
      vs. controls < 
0.001 
Low malignant 
potential 
tumors 
0.17 0.09 0.16 0.06 0.37 vs. benign 
tumors 
0.020 
 
High grade 
tumors 
 
0.89 
 
0.72 
 
0.67 
 
0.14 
 
2.37 
 
vs. low 
malignant 
potential 
tumors 
 
< 
0.001 
 
Stage I-II 
tumors 
 
0.19 
 
0.15 
 
0.16 
 
0.06 
 
0.69 
 
vs. benign 
tumors 
 
0.017 
 
Stage III-IV 
tumors 
 
0.87 
 
0.72 
 
0.64 
 
0.14 
 
2.37 
 
vs. stage I-II 
tumors 
 
< 
0.001 
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Fig. 1 Study population 295 
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Fig. 2 The urinary concentrations of N
1
,N
12
-diacetylspermine (DiAcSpm) (µmol/g creatinine) in patients with 298 
ovarian tumors and in controls and comparisons between the groups  299 
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Fig. 3 The urinary concentrations of  N
1
,N
12
-diacetylspermine (DiAcSpm) (µmol/g creatinine) in the women 302 
with stage I-II and stage III-IV ovarian tumors  303 
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Fig. 4 ROC-curves for urinary N
1
,N
12
-diacetylspermine (DiAcSpm)  and CA125 in benign and malignant 306 
ovarian tumors with optimal (DiAcSpm 0.097 µmol/g creatinine) and typically used (CA125 35 kU/L) 307 
thresholds 308 
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